Why Ignite+
Sima Sistani, WW's CEO, said in a statement that as science "advances rapidly" with medications to treat obesity, WW is evolving as well." "Clinical interventions require better education, access, care management, community and the integration of a complementary lifestyle program for best results," Sistani said
Walk away from any seller claiming the copy is the same as the approved drug, any price too good to believe, any platform that skips the prescription step, and any product made from semaglutide salt forms (sodium or acetate), which the agency says have no lawful basis in compounding
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Comparison Between Established and the Worldwide Esophageal Cancer Collaboration Staging Systems
Evidence: Well-validated across many injury types
